000117353 001__ 117353 000117353 005__ 20230519145532.0 000117353 0247_ $$2doi$$a10.1111/jdv.17370 000117353 0248_ $$2sideral$$a126863 000117353 037__ $$aART-2021-126863 000117353 041__ $$aeng 000117353 100__ $$aChernyshov P.V. 000117353 245__ $$aQuality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes 000117353 260__ $$c2021 000117353 5060_ $$aAccess copy available to the general public$$fUnrestricted 000117353 5203_ $$aNew treatment options may lead to an increased interest in using reliable and sensitive instruments to assess health-related quality of life in people with alopecia areata (AA). The purpose of this paper is to present current knowledge about quality of life assessment in AA. The dermatology-specific Dermatology Life Quality Index (DLQI) was the most widely reported health-related quality of life instrument used in AA. Three AA-specific (Alopecia Areata Symptom Impact Scale, Alopecia Areata Quality of Life Index and Alopecia Areata Patients'' Quality of Life) and three hair disease-specific instruments (Hairdex, Scalpdex and ‘hair-specific Skindex-29’) were identified with a range of content and validation characteristics: there is little evidence yet of the actual use of these measures in AA. Scalpdex is the best-validated hair disease-specific instrument. Further extensive validation is needed for all of the AA-specific instruments. The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes recommends the use of the dermatology-specific DLQI questionnaire, hair disease-specific Scalpdex and the alopecia areata-specific instruments the Alopecia Areata Symptom Impact Scale or Alopecia Areata Quality of Life Index, despite the limited experience of their use. We hope that new treatment methods will be able to improve both clinical signs and health-related quality of life in patients with AA. In order to assess the outcomes of trials on these new treatment methods, it would be helpful when further development and validation of AA-specific instruments is being encouraged and also conducted. © 2021 European Academy of Dermatology and Venereology. 000117353 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000117353 590__ $$a9.228$$b2021 000117353 592__ $$a1.613$$b2021 000117353 594__ $$a9.1$$b2021 000117353 591__ $$aDERMATOLOGY$$b4 / 70 = 0.057$$c2021$$dQ1$$eT1 000117353 593__ $$aInfectious Diseases$$c2021$$dQ1 000117353 593__ $$aDermatology$$c2021$$dQ1 000117353 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000117353 700__ $$0(orcid)0000-0003-1917-6906$$aTomas-Aragones L.$$uUniversidad de Zaragoza 000117353 700__ $$aFinlay A.Y. 000117353 700__ $$aManolache L. 000117353 700__ $$0(orcid)0000-0001-5632-0351$$aMarron S.E.$$uUniversidad de Zaragoza 000117353 700__ $$aSampogna F. 000117353 700__ $$aSpillekom-van Koulil S. 000117353 700__ $$aPustisek N. 000117353 700__ $$aSuru A. 000117353 700__ $$aEvers A.W.M. 000117353 700__ $$aSalavastru C. 000117353 700__ $$aSvensson A. 000117353 700__ $$aAbeni D. 000117353 700__ $$aBlome C. 000117353 700__ $$aPoot F. 000117353 700__ $$aJemec G.B.E. 000117353 700__ $$aLinder D. 000117353 700__ $$aAugustin M. 000117353 700__ $$aBewley A. 000117353 700__ $$aSalek S.S. 000117353 700__ $$aSzepietowski J.C. 000117353 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac 000117353 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología 000117353 773__ $$g35, 8 (2021), 1614-1621$$pJEADV, J. Eur. Acad. Dermatol. Venereol.$$tJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY$$x0926-9959 000117353 8564_ $$s1019323$$uhttps://zaguan.unizar.es/record/117353/files/texto_completo.pdf$$yVersión publicada 000117353 8564_ $$s2115083$$uhttps://zaguan.unizar.es/record/117353/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000117353 909CO $$ooai:zaguan.unizar.es:117353$$particulos$$pdriver 000117353 951__ $$a2023-05-18-15:31:38 000117353 980__ $$aARTICLE